Markets:

Overview

News

Currencies

International

Treasuries

Vericel Corporation - Common Stock (NQ:VCEL)

39.77 +0.33 (+0.84%)

Delayed Quote Updated: 2:59 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Vericel Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >

Vericel to Report Fourth-Quarter 2022 Financial Results on February 23, 2023

February 09, 2023

From Vericel Corporation

Via GlobeNewswire

Analyst Ratings for Vericel ↗

January 27, 2023

Via Benzinga

2022 Was A Year Of Growth, Funding, And Positive Results For BioRestorative Therapies ↗

January 25, 2023

BioRestorative Therapies Inc. (NASDAQ: BRTX) (“BioRestorative”) may have had a successful year of novel drug development.

Via Benzinga

What's Going On With Vericel Shares Trading Higher ↗

January 10, 2023

Vericel Corp (NASDAQ: VCEL) shares are trading higher by 13.63% to $27.10 Tuesday after the company reported preliminary FY22 revenue results. What Else?

Via Benzinga

Vericel Announces Preliminary Fourth-Quarter and Full-Year 2022 Financial Results and Accelerated Launch Timeline for MACI Arthroscopic Program

January 10, 2023

From Vericel Corporation

Via GlobeNewswire

FDA Approves MediWound's NexoBrid For Burn Treatment ↗

December 30, 2022

Via Benzinga

Looking Into Vericel's Return On Capital Employed ↗

December 14, 2022

Via Benzinga

Vericel: Q2 Earnings Insights ↗

August 03, 2022

Vericel (NASDAQ:VCEL) reported its Q2 earnings results on Wednesday, August 3, 2022 at 08:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

Why Bed Bath & Beyond Shares Are Trading Higher By 17%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

January 10, 2023

Gainers

Via Benzinga

Vericel to Present at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023

January 04, 2023

From Vericel Corporation

Via GlobeNewswire

Vericel: Q1 Earnings Insights ↗

May 04, 2022

Vericel (NASDAQ:VCEL) reported its Q1 earnings results on Wednesday, May 4, 2022 at 08:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

MediWound Announces FDA Approval of NexoBrid® for the Treatment of Severe Thermal Burns in Adults

December 29, 2022

From MediWound Ltd.

Via GlobeNewswire

Vericel Announces FDA Approval of NexoBrid for the Treatment of Severe Thermal Burns in Adults

December 29, 2022

From Vericel Corporation

Via GlobeNewswire

Biogen's 2nd Alzheimer's Antibody, BeiGene's Cancer Drug Label Expansion, Adcom Test For Regeneron And More: January PDUFA Catalysts For Biotech Investors ↗

December 27, 2022

Biopharma stocks were not immune to the broader market downturn seen for much of 2022.

Via Benzinga

Chronic Obstructive Pulmonary Disease (COPD) Market Expected to Reach $25 Billion By 2027

November 15, 2022

EQNX::TICKER_START (OTCQB:OCEL),(NASDAQ:BRTX),(NASDAQ:MDXG),(NYSE:NNVC),(NASDAQ:VCEL) EQNX::TICKER_END

Via FinancialNewsMedia

Why Apyx Medical Shares Dipped Over 60%; Here Are 123 Biggest Movers From Yesterday ↗

November 11, 2022

Gainers

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For November 10, 2022 ↗

November 10, 2022

Upgrades

Via Benzinga

Vericel to Participate in the Canaccord Genuity MedTech, Diagnostics, and Digital Health & Service Forum and the Stephens Annual Investment Conference

November 10, 2022

From Vericel Corporation

Via GlobeNewswire

Vericel Reports Third Quarter 2022 Financial Results

November 09, 2022

From Vericel Corporation

Via GlobeNewswire

Why Merrimack Pharmaceuticals Shares Jumped Around 213%; Here Are 114 Biggest Movers From Yesterday ↗

November 10, 2022

Gainers

Via Benzinga

Vericel to Report Third-Quarter 2022 Financial Results on November 9, 2022

October 26, 2022

From Vericel Corporation

Via GlobeNewswire

FDA Accepts MediWound's Refiling For Severe Thermal Burns Therapy For Review ↗

August 03, 2022

The U.S. Food and Drug Administration (FDA) has accepted for review MediWound’s (NASDAQ: MDWD) recently re-submitted Biologics License Application (BLA) for its lead asset NexoBrid for eschar removal...

Via Benzinga

Vericel Earnings Perspective: Return On Capital Employed ↗

May 20, 2022

Benzinga Pro data, Vericel (NASDAQ:VCEL) reported Q1 sales of $36.07 million. Earnings fell to a loss of $7.09 million, resulting in a 256.4% decrease from last quarter. Vericel earned $4.53 million,...

Via Benzinga

Earnings Scheduled For May 4, 2022 ↗

May 04, 2022

Companies Reporting Before The Bell • Seres Therapeutics (NASDAQ:MCRB) is estimated to report quarterly loss at $0.52 per share on revenue of $8.48 million.

Via Benzinga

Stocks That Hit 52-Week Lows On Tuesday ↗

June 14, 2022

On Tuesday, 951 companies hit new 52-week lows.

Via Benzinga

Vericel Q1 2022 Earnings Conference Call On May 4, 2022 At 08:30 AM ET ↗

April 25, 2022

Vericel (NASDAQ:VCEL) will host a conference call at 08:30 AM ET on May 4, 2022, to discuss Q1 2022 earnings results. How to Attend Vericel (VCEL) Conference Call Follow this link to access the live...

Via Benzinga

88 Biggest Movers From Yesterday ↗

February 25, 2022

Gainers Cyren Ltd. (NASDAQ: CYRN) shares surged 118.9% to settle at $4.75 on Thursday. Cyren recently announced a $12 million private placement. Indonesia Energy Corporation...

Via Benzinga

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

February 24, 2022

Gainers Lantheus Holdings (NASDAQ:LNTH) stock rose 33.3% to $38.46 during Thursday's regular session. The current volume of 3.4 million shares is 876.7% of Lantheus...

Via Benzinga

The Daily Biotech Pulse: Orphazyme Plunges On Regulatory Setback In Europe, Pulmonx Earnings Disappoint, Amicus Declines To Spin Off Genetic Medicine Company ↗

February 24, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Adagio Appoints COO David Hering As Interim CEO Adagio Therapeutics, Inc., (...

Via Benzinga

The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow ↗

February 20, 2022

Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries. On the regulatory front...

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.